With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.
GLP-1 drugs are big business, and investors can win rewards by searching beyond the biggest names or diversifying via ETFs.
As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.
Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver disease....
Eli Lilly and Company LLY reported robust second-quarter 2025 results, wherein it beat estimates on both the top and bottom lines, driven by strong demand for its blockbuster weight loss and diabetes drugs....
Wall Street ended February on a dismal note, weighed down by economic slowdown concerns and Trump’s tariff plans. The tech-heavy Nasdaq Composite suffered its biggest monthly decline since April 2024,...
Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments.
Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight-loss medicine...
JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity.
The pharma giant expects continued growth for Mounjaro and Zepbound this year, supported by expanded manufacturing capacity and new market launches.